All Stories

  1. Macrophage trafficking and efferocytosis in atherosclerotic plaque regression: Molecular mechanisms and therapeutic perspectives
  2. Metformin as a promising therapeutic option for reducing substance withdrawal syndromes: A narrative review
  3. The impact of phytochemicals on statin efficacy and safety: A review
  4. The impact of sleep disturbance on post-transplant recovery and quality of life: Neural mechanisms and translational management strategies
  5. Therapeutic potential of Bowman-Birk inhibitors in various disorders: A comprehensive review
  6. Nanomedicine solutions for inhibiting anastasis and inducing apoptosis to mitigate relapse in treatment-resistant cancers
  7. Synergistic modulation of p53-HMGB1 complex and its binding to DNA: The role of nanotechnology in overcoming cancer drug resistance; A literature review and in-silico analysis
  8. MicroRNAs in the abscopal effect: bridging radiotherapy and systemic anti-tumor immunity for enhanced cancer therapy
  9. The interplay between gut microbiome, epigenetics, and substance use disorders: from molecular to clinical perspectives
  10. Modulation of Neuroinflammation in Poststroke Rehabilitation: The Role of 12/15-Lipoxygenase Inhibition and Baicalein
  11. Advancements in microfluidic platforms for rapid biomarker diagnostics of infectious diseases
  12. MicroRNA-mediated regulation of Ferroptosis: Implications for disease pathogenesis and therapeutic interventions
  13. Phytochemical-mediated efferocytosis and autophagy in inflammation control
  14. Modulation of efferocytosis and inflammation resolution by live and non-live probiotics through gut microbiota interactions in preclinical and clinical studies
  15. Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials
  16. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
  17. Advancing stroke recovery: unlocking the potential of cellular dynamics in stroke recovery
  18. MicroRNAs and proteolytic cleavage of receptors in cancers: A comprehensive review of regulatory interactions and therapeutic implications
  19. Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions
  20. The Regulation, Functions, and Signaling of miR-153 in Neurological Disorders, and Its Potential as a Biomarker and Therapeutic Target
  21. The role of efferocytosis and transplant rejection: Strategies in promoting transplantation tolerance using apoptotic cell therapy and/or synthetic particles
  22. Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value in a Variety of Neurological Disorders
  23. Recent advances and applications of peptide–agent conjugates for targeting tumor cells
  24. Exosomal microRNAs and long noncoding RNAs: as novel biomarkers for endometriosis
  25. The Role of Gut Microbiota in Inflammatory Bowel Disease-Current State of the Art
  26. Cell membrane biomimetic nanoparticles in drug delivery
  27. Biomimetic Nanovaccines: A Novel Approach in Immunization
  28. Macrophage efferocytosis in health and disease
  29. Exosomal lncRNAs in gastrointestinal cancer
  30. Identification of a Missense Mutation in GJA8 Gene in an Iranian Family with Autosomal Dominant Congenital Cataract
  31. Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy
  32. Statin-regulated phagocytosis and efferocytosis in physiological and pathological conditions
  33. The regulation of efferocytosis signaling pathways and adipose tissue homeostasis in physiological conditions and obesity: Current understanding and treatment options
  34. Recent findings on the role of microRNAs in genetic kidney diseases
  35. The cross‐talk between soluble “Find me” and “Keep out” signals as an initial step in regulating efferocytosis
  36. The role of miR-153 and related upstream/downstream pathways in cancers: from a potential biomarker to treatment of tumor resistance and a therapeutic target
  37. 2q35-rs13387042 variant and the risk of breast cancer: a case–control study
  38. Potential diagnostic and prognostic of efferocytosis-related unwanted soluble receptors/ligands as new non-invasive biomarkers in disorders: a review
  39. COVID-19 and Acute Kidney Injury: A Systematic Review
  40. Evaluation of Oxygen Saturation as an Indicator for Tracheal Intubation in Patients With COVID-19: A Prospective Cohort Study
  41. The Significant Role of a Functional Polymorphism in the NF-κB1 Gene in Breast Cancer: Evidence from an Iranian Cohort
  42. The Effect of Cigarette Smoke Exposure on Efferocytosis in Chronic Obstructive Pulmonary Disease; Molecular Mechanisms and Treatment Opportunities
  43. CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
  44. Bispecific Antibodies in Colorectal Cancer Therapy: Recent Insights and Emerging Concepts
  45. Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
  46. Cholangiocarcinoma and liver transplantation: What we know so far?
  47. Gold Nanobiosensor Based on the Localized Surface Plasmon Resonance is Able to Diagnose Human Brucellosis, Introducing a Rapid and Affordable Method
  48. Quercetin and its role in modulating endoplasmic reticulum stress: A review
  49. The complex roles of efferocytosis in cancer development, metastasis, and treatment
  50. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
  51. Evaluating the Association between CCR5delta32 Polymorphism (rs333) and the Risk of Breast Cancer in a Cohort of Iranian Population
  52. Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks
  53. Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population: a case–control study
  54. Association of PICK1 and BDNF Variations with Increased Risk of Methamphetamine Dependence Among Iranian Population; A Case-Control Study
  55. MicroRNAs in temporal lobe epilepsy: a systematic review
  56. Autoantigen-specific immune tolerance in pathological and physiological cell death: Nanotechnology comes into view
  57. Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives
  58. Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons
  59. Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity
  60. Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population; a case-control study
  61. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse
  62. Association of PICK1 and BDNF variations with increased risk of methamphetamine dependence among Iranian population; a case-control study
  63. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up
  64. Association of PICK1 and BDNF Variations with Increased Risk of Methamphetamine Dependence Among Iranian population; A Case-Control Study
  65. Regulation of efferocytosis by caspase-dependent apoptotic cell death in atherosclerosis
  66. The role of nuclear factors as “Find-Me”/alarmin signals and immunostimulation in defective efferocytosis and related disorders
  67. Ca2+ Flux: Searching for a Role in Efferocytosis of Apoptotic Cells in Atherosclerosis
  68. Prevalence of CCR5delta32 in Northeastern Iran
  69. 50 bp deletion in promoter superoxide dismutase 1 gene and increasing risk of cardiovascular disease in Mashhad stroke and heart atherosclerotic disorder cohort study
  70. The Impact of CASP8 rs10931936 and rs1045485 Polymorphisms as well as the Haplotypes on Breast Cancer Risk: A Case-Control Study
  71. Efferocytosis and Atherosclerosis: Regulation of Phagocyte Function by MicroRNAs
  72. Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review
  73. Association of rs4784227-CASC16 (LOC643714 locus) and rs4782447-ACSF3 polymorphisms and their association with breast cancer risk among Iranian population
  74. A method for improving the efficiency of DNA extraction from clotted blood samples
  75. Association between HBV and HTLV-1 infections and breast cancer risk: a population-based case-control study in Iran
  76. Effect of soluble cleavage products of important receptors/ligands on efferocytosis: Their role in inflammatory, autoimmune and cardiovascular disease
  77. Improving the Training Process of Anesthesiology Residents Through the Mentorship-Based Approach
  78. Significant association of TOX3/LOC643714 locus-rs3803662 and breast cancer risk in a cohort of Iranian population
  79. The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer
  80. The clinical importance of CD4 + CD7 − in human diseases
  81. Efferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms
  82. The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer
  83. Paraoxonase 1 (PON1) and stroke; the dilemma of genetic variation
  84. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways
  85. Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives
  86. The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
  87. Association of tumor necrosis factor-α promoter G-308A gene polymorphism with increased triglyceride level of subjects with metabolic syndrome
  88. Impact of the C1431T Polymorphism of the Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ) Gene on Fasted Serum Lipid Levels in Patients with Coronary Artery Disease